← Back to patent-cliff list

CAS 979-02-2

(3S,8R,9S,10R,13S,14S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

Codes: PRAS-010, GALE-006

Application context (from source-drug indications)

Vulvovaginal atrophyPrasteroneAtrophyPrasteroneDyspareuniaPrasteroneBreast cancerPrasteroneVaginal diseasePrasteroneAnal neoplasmPrasteronePancreatic cancerGaleteroneProstate cancerGaleterone

Source drugs (routes using this intermediate)

DrugTierExpiry
PrasteroneTier C — Watch / trade-
GaleteroneTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

PrasteroneOptimised routesteps: 3total yield: 70 g
hydrazinecarboxamide hydrochloride→(3S,8R,9S,10R,13S,14S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate→(8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate
GaleteroneProcess routesteps: 2total yield: 134.00 kg (Galeterone)
(3S,8R,9S,10R,13S,14S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate→(3S,8R,9S,10R,13S,14S)-17-((Z)-1-(hydroxyimino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.